Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 8/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745466 | 0.86 | BTK (0.36) | BTKGRM5 | |
| SCHEMBL31745551 | 0.86 | BTK (0.38) | BTKGRM5KDM4EMAPTHTT | |
| SCHEMBL31745482 | 0.85 | KDM4E (0.35) | TNK2DRD1AOC3KDM4EMAPT | |
| SCHEMBL31360346 | 0.81 | BTK (0.38) | BTKTGFBR1SYKGRM5KDM4E | |
| SCHEMBL31745472 | 0.78 | BTK (0.40) | BTK | |
| SCHEMBL31745513 | 0.78 | BTK (0.37) | BTKGRM5 | |
| SCHEMBL31745546 | 0.77 | FYN (0.36) | TGFBR1GRM5PPARG | |
| SCHEMBL31745493 | 0.76 | BTK (0.35) | TNK2BTKKDM4EMAPTHTT | |
| SCHEMBL31745433 | 0.75 | BTK (0.40) | BTK | |
| SCHEMBL31745492 | 0.75 | GRM5 (0.36) | BTKTGFBR1GRM5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | TNK2 452/4885BTK 178/4885TGFBR1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.